References
- Caujolle FME, Caujolle DH. (1967). Limits of tolerance and teratogenic tolerance of dimethyl sulfoxide. Ann NY Acad Sci 141:110–25
- Cheung WMW, Ng WW, Kung AW. (2006). Dimethyl sulfoxide as an inducer of differentiation in preosteoblast MC3T3-E1 cells. FEBS Lett 580:121–6
- Council Chemical-Biological Coordination Center. (1953). Summary tables of biological tests. Washington (DC): National Research Council Chemical-Biological Coordination Center, National Academy of Science Library, Vol. 5:339
- Duchene D. (1991). New trends in cyclodextrins and derivatives. Paris: Editions de Sante
- Evans JM, Latto IP, Ng WS. (1974). Accidental intra-arterial injection of drugs: a hazard of arterial cannulation: 3 case reports. Br J Anaesth 46:463–6
- Fabry ME, Costantini F, Pachnis A, et al. (1992). High expression of human βs- and α-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci USA 89:12155–9
- Fonge H, Jin L, Wang H, et al. (2008a). Synthesis and preliminary biological evaluation of a 99mTc-labeled hypericin derivative as a necrosis avid imaging agent. J Label Compd Radiopharm 51:33–40
- Fonge H, Vunckx K, Wang H, et al. (2008b). Noninvasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin µSPECT. Eur Heart J 29:260–9
- Katholieke Universiteit Leuven-Oncocidia (2012). Available from: http://vimeo.com/44871398 [last accessed 12 Oct 2012]
- Kelada E, Jones A. (2007). Interstitial cystitis. Arch Gynecol Obstet 275:223–9
- Kubin A, Meissner P, Wierrani F, et al. (2008). Fluorescence diagnosis of bladder cancer with new water soluble hypericin bound to polyvinylpyrrolidone: PVP-hypericin. Photochem Photobiol 84:1560–3
- Li J, Cona MM, Feng YB, et al. (2012). A single-dose toxicity study in mice on non-radioactive iodinated hypericin for a targeted anticancer therapy. Acta Pharmacol Sin 33:1549–56
- Li J, Sun Z, Zhang J, et al. (2011). A new anticancer approach based on the soil-and-seeds principle. Radiology 260:799–807
- Litchfield J, Wilcoxon F. (1949). A simplified method of evaluating dose effect experiments. J Pharmacol Exp Ther 96:99–113
- Ni Y, Huyghe D, Verbeke K, et al. (2006). First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 33:595–601
- Ni Y, van de Putte M, de Witte P, et al. (2012). European patent EP2219683B1: Targeted radiotherapy
- Sgarbossa A, Angelini N, Gioffré D, et al. (2000). The uptake, location and fluorescence of hypericin in bovine intact lens. Curr Eye Res 21:597–601
- Sgarbossa A, Lenci F. (2001). Spectroscopic study of visible-light effects on hypericin-lens proteins systems. Photochem Photobiol 74:196–200
- Stephens AS, Stephens SR, Hobbs C, et al. (2011). Myocyte enhancer factor 2c: an osteoblast transcription factor identified by DMSO-enhanced mineralization. J Biol Chem 286:30071–86
- Sun ZP, Ni Y. (2009). Patent CN 200910013998: Iodogen method for preparation of radioiodinated Hypericin
- Tallarida RJ, Murray RB. (1987). Manual of pharmacological calculations with computer programs. 2nd ed. New York: Springer, 59–63
- Unak T, Akgün Z, Yildirim Y, et al. (2001). Self-radioiodination of iodogen. Appl Radiat Isot 54:749–52
- van de Putte M, Roskams T, Bormans G, et al. (2006). The impact of aggregation on the biodistribution of hypericin. Int J Oncol 28:655–60
- Walker M. (1993). DMSO: nature’s healer. Garden City Park (NY): Avery Publishing Group Inc., 61–3
- Willson JE, Brown DE, Timmens EK. (1965). A toxicologic study of dimethyl sulfoxide. Toxicol Appl Pharmacol 1:104–12